



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/790,715	03/03/2004	Gregory M. Glenn	056707-5001-01	4303
9629	7590	04/24/2006	EXAMINER	
MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004			KIM, YUNSOO	
		ART UNIT	PAPER NUMBER	
		1644		

DATE MAILED: 04/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/790,715	GLENN ET AL.
	Examiner Yunsoo Kim	Art Unit 1644

*-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --*

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) Responsive to communication(s) filed on 24 March 2006.
- 2a) This action is FINAL.                            2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) Claim(s) 106-159 and 161 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 106-159 and 161 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
 

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date: _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date: _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

### **DETAILED ACTION**

1. Applicants' After Final amendment filed 3/24/06 has been considered.

Upon consideration of Applicants' arguments, the finality of the last office action mailed 1/24/06 has been withdrawn.

2. Claims 106-110 and 142 have been amended and claim 160 has been canceled.

Claims 106-159 and 161 are pending and under consideration.

3. Upon Applicant's amendment to claim 142, the rejections the first paragraph of 35 U.S.C. 112 (sections 6-7) set forth in the office action mailed 1/24/06 have been withdrawn.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 142-159 and 161 stand rejected under 35 U.S.C. 112, first paragraph as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected to make and/or use the invention. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Applicants' arguments and French et al. reference filed on 3/24/06 have been fully considered but they are not persuasive.

Applicants traversed the rejection based on that the multiple applications of antigenic compositions to local or distal sites enhanced immune responses (French et al. provided by Applicants) and provision of example 12 enables multiple applications.

Factors to be considered in determining whether undue experimentation is required to practice the claimed invention are summarized *In re Wands* (858 F2d 731, 737, 8 USPQ2d 1400, 1404 (Fed.Cir.1988)). The factors most relevant to this rejection are the scope of the claim, the amount of direction or guidance provided, the lack of sufficient working examples, the unpredictability in the art and the amount of experimentation required to enable one of the skilled in the art to practice the claimed invention.

The specification does not reasonably provide enablement for a method of inducing an immune response comprising applying a formulation to more than one application area including any area of skin and the first parenteral administration and consequent transdermal application of antigen and adjuvant.

The antigenic stimulation at an application site results the lymph collected is filtered through a set of defined lymph nodes of the local area. Distal and multiple applications of antigens to cervical and abdomen areas would not result one draining lymph node (Kuby, 2000, Immunology, 4<sup>th</sup> ed. p. 47-53, of record).

Furthermore, the claim 142 and the dependent claims thereof as amended recite “parenteral” administration of the first administration of antigen and applying the adjuvant formulation to any area of skin after pretreatment. The example representing the sequential applications of an antigen and an adjuvant formulation at different sites does not teach “parenteral” administration but transdermal administration (Example. 13, p. 34 immunization procedure).

The French et al. teach the enhancement of immune response of multiple application of antigen/adjuvant parenterally to one site and the second LT application transcutaneously 5cm to the first site which still result from one defined lymph nodes. However, the claim 142 as drafted is not limited to the scope supported by Example 12 or French. et al. reference.

Thus, Applicant has not provided any guidance to enable one skill in the art to use claimed invention in manner reasonably correlated with the scope of enablement. In view of the quantity of experimentation necessary, the limited working example, the unpredictability of the art, the lack of sufficient guidance in the specification, and the breadth of the claims, it would take undue trials and errors to practice the claimed invention.

Art Unit: 1644

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 106, 107, 109, 110, 114-121, 124, 125, 127, 128 and 132-139 stand rejected under 35 U.S.C. 102(b) as being anticipated by WO 95/17211(IDS reference, of record) as is evidenced by the Skills Checklist for immunization for the reasons set forth in the office action mailed 1/24/06.

Applicants' arguments filed on 3/24/06 have been fully considered but they are not persuasive.

Applicants traversed the rejection based on that the reference does not teach inducing immune response by applying to the skin and pretreatment was not taught.

Contrary to Applicants' argument that the reference teaching is limited to mucosal delivery of antigen and adjuvant, the '212 publication teaches applying the immunogenic composition "transdermally" (p. 12, lines 12-13) as well as conventional administration.

In addition, as evidenced by the Skills Checklist, the pretreatment of skin by chemical or hydration means (i.e. cleaning the skin with alcohol before application of medication) is well known procedure, rather inherent process of immunization. As the claimed invention is not limited to transcutaneous delivery of antigen with the pretreatment to disrupt the skin barrier of stratum corneum or superficial epidermis, the reference teaching reads on the claimed invention. Thus, the reference teachings anticipate the claimed invention.

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office Action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 106 - 108, 113, 122-126, 131, 140 and 141 stand rejected under 35 U.S.C. 103 as being unpatentable over WO 95/17211(IDS reference, of record) as is evidenced by Skill Checklist for immunization, in view of U.S. Pat. No.4, 810,499 (IDS reference, of record) for the reasons set forth in the office action mailed 1/24/06.

Applicants' arguments filed on 3/24/06 have been fully considered but they are not persuasive.

Applicants traversed the rejection based on that the deficiency of the '211 publication thus the combination is not obvious.

In light of the discussion of the '211 publication teaches transdermal and pretreatment to hydrate before immunization being well known and inherent process of immunization, the combination of the reference teachings remain obvious.

From the teachings of references, one of the ordinary skill in art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of the ordinary in the art at the time the invention was made, as evidenced by references, especially in the absence of evidence to the contrary.

10. Claims 106, 111, 112, 124, 129 and 139 are rejected under 35 U.S.C. 103 as being unpatentable over WO 95/17211 (IDS reference, of record) as is evidenced by the Skill checklist for immunization, in view of U.S. Pat. No.5,814,599 (IDS reference, of record) for the reasons set forth in the office mailed 1/24/06.

Applicants' arguments filed on 3/24/06 have been fully considered but they are not persuasive.

Applicants traversed the rejection based on that the deficiency of the '211 publication thus the combination is not obvious.

In light of the discussion of the '211 publication teaches transdermal and pretreatment to hydrate before immunization being well known and inherent process of immunization, the combination of the reference teachings remain obvious.

From the teachings of references, one of the ordinary skill in art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of the ordinary in the art at the time the invention was made, as evidenced by references, especially in the absence of evidence to the contrary.

11. No claims are allowable.

12. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yunsoo Kim whose telephone number is 571-272-3176. The examiner can normally be reached on Monday thru Friday 8:30 - 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yunsoo Kim  
Patent Examiner  
Technology Center 1600  
April 14, 2006

*Pat J. Nolan*  
Patrick, J. Nolan, Ph.D.  
Primary Examiner  
Technology Center 1600